NIH VideoCast - The two faces of the IL-15- Janus Kinase-Stat system: implications for the immunotherapy of autoimmune diseases and cancer

Skip Navigation

The two faces of the IL-15- Janus Kinase-Stat system: implications for the immunotherapy of autoimmune diseases and cancer

0 seconds of 0 secondsVolume 90%

00:25

00:00

00:00

448 Views

Air date:	Wednesday, November 29, 2017, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 448 (154 Live, 294 On-demand)
Category:	WALS - Wednesday Afternoon Lectures
Runtime:	01:09:28
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH Director's Wednesday Afternoon Lecture Series Dr. Walmann will present the annual William Paul lecture. Dr. Waldmann defined the IL-2 receptor alpha and beta subunits using the daclizumab antibody he discovered, an antibody that is approved by the FDA. He co-discovered IL-15 and performed the first in-human clinical trial with this agent in patients with malignancy. Furthermore, Waldmann defined molecular abnormalities of the common gamma cytokine, Jak/Stat signaling pathway in HTLV-1 associated adult T-cell lymphoma and translated this discovery with a trial of a Jak inhibitor in patients with this disorder. For more information go to https://oir.nih.gov/wals

NLM Title:	The two faces of the IL-15- Janus Kinase-Stat system : implications for the immunotherapy of autoimmune diseases and cancer / Thomas A. Waldmann.
Author:	Waldmann, Thomas.
Publisher:
Abstract:	(CIT): NIH Director's Wednesday Afternoon Lecture Series Dr. Walmann will present the annual William Paul lecture. Dr. Waldmann defined the IL-2 receptor alpha and beta subunits using the daclizumab antibody he discovered, an antibody that is approved by the FDA. He co-discovered IL-15 and performed the first in-human clinical trial with this agent in patients with malignancy. Furthermore, Waldmann defined molecular abnormalities of the common gamma cytokine, Jak/Stat signaling pathway in HTLV-1 associated adult T-cell lymphoma and translated this discovery with a trial of a Jak inhibitor in patients with this disorder.
Subjects:	Autoimmune Diseases--therapy Interleukin-15--immunology Interleukin-15--therapeutic use Janus Kinases Neoplasms--therapy STAT Transcription Factors
Publication Types:	Lecture Webcast

NLM Classification:	QW 568
NLM ID:	101718226
CIT Live ID:	26622
Permanent link:	https://videocast.nih.gov/watch=26622

Related Videos...